Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E-β-thalassemia): a single center study from eastern India. (opens new window)

Bohara VV, Ray S, Chakrabarti P, Ray SS, Nath UK, Chaudhuri U.

Źródło‎: Hemoglobin 2014;38(1):44-8.

Indeks‎: PubMed 24144212

DOI‎: 10.3109/03630269.2013.845844

https://www.ncbi.nlm.nih.gov/pubmed/24144212 (opens new window)

Hydroxyurea in thalassemia intermedia--a promising therapy. (opens new window)

Dixit A, Chatterjee TC, Mishra P, Choudhry DR, Mahapatra M, Tyagi S, Kabra M, Saxena R, Choudhry VP.

Źródło‎: Ann Hematol 2005;84(7):441-6.

Indeks‎: PubMed 15838670

DOI‎: 10.1007/s00277-005-1026-4

https://www.ncbi.nlm.nih.gov/pubmed/15838670 (opens new window)

Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study. (opens new window)

Italia KY, Jijina FF, Merchant R, Panjwani S, Nadkarni AH, Sawant PM, Nair SB, Ghosh K, Colah RB.

Źródło‎: J Clin Pathol 2010;63(2):147-50.

Indeks‎: PubMed 20154037

DOI‎: 10.1136/jcp.2009.070391

https://www.ncbi.nlm.nih.gov/pubmed/20154037 (opens new window)

Echocardiographic finding in beta-thalassemia intermedia and major: absence of pulmonary hypertension following hydroxyurea treatment in beta-thalassemia intermedia. (opens new window)

Karimi M, Borzouee M, Mehrabani A, Cohan N.

Źródło‎: Eur J Haematol 2009;82(3):213-8.

Indeks‎: PubMed 19077048

DOI‎: 10.1111/j.1600-0609.2008.01192.x

https://www.ncbi.nlm.nih.gov/pubmed/19077048 (opens new window)

Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. (opens new window)

Karimi M, Mohammadi F, Behmanesh F, Samani SM, Borzouee M, Amoozgar H, Haghpanah S.

Źródło‎: Eur J Haematol 2010;84(1):52-8.

Indeks‎: PubMed 19799627

DOI‎: 10.1111/j.1600-0609.2009.01356.x

https://www.ncbi.nlm.nih.gov/pubmed/19799627 (opens new window)

Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece. (opens new window)

Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I.

Źródło‎: Blood Cells Mol Dis 2000;26(5):453-66.

Indeks‎: PubMed 11112383

DOI‎: 10.1006/bcmd.2000.0328

https://www.ncbi.nlm.nih.gov/pubmed/11112383 (opens new window)

Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. (opens new window)

Perrine SP.

Źródło‎: Pediatr Ann 2008;37(5):339-46.

Indeks‎: PubMed 18543545

https://www.ncbi.nlm.nih.gov/pubmed/18543545 (opens new window)

Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-beta 0-thalassemia: Considerations for treatment. (opens new window)

Singer ST, Kuypers FA, Olivieri NF, Weatherall DJ, Mignacca R, Coates TD, Davies S, Sweeters N, Vichinsky EP.

Źródło‎: Ann N Y Acad Sci 2005;1054:250-6.

Indeks‎: PubMed 16339672

DOI‎: 10.1196/annals.1345.031

https://www.ncbi.nlm.nih.gov/pubmed/16339672 (opens new window)

Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. (opens new window)

Chaidos A, Makis A, Hatzimichael E, Tsiara S, Gouva M, Tzouvara E, Bourantas KL.

Źródło‎: Acta Haematol 2004;111(4):189-95.

Indeks‎: PubMed 15153710

DOI‎: 10.1159/000077551

https://www.ncbi.nlm.nih.gov/pubmed/15153710 (opens new window)

Efficacy of erythropoietin on dialysis in patients with beta thalassemia minor. (opens new window)

Di Iorio B, De Nicola L, Bellizzi V, Minutolo R, Zamboli P, Rubino R, Fuiano G, Conte G.

Źródło‎: Blood Purif 2004;22(5):453-60.

Indeks‎: PubMed 15359104

DOI‎: 10.1159/000080729

https://www.ncbi.nlm.nih.gov/pubmed/15359104 (opens new window)

The role of recombinant human erythropoietin in the treatment of thalassemia. (opens new window)

Rachmilewitz EA, Aker M.

Źródło‎: Ann N Y Acad Sci 1998;850:129-38.

Indeks‎: PubMed 9668535

https://www.ncbi.nlm.nih.gov/pubmed/9668535 (opens new window)

Darbepoetin alfa for the treatment of anaemia in alpha- or beta- thalassaemia intermedia syndromes. (opens new window)

Singer ST, Vichinsky EP, Sweeters N, Rachmilewitz E.

Źródło‎: Br J Haematol 2011;154(2):281-4.

Indeks‎: PubMed 21496003

DOI‎: 10.1111/j.1365-2141.2011.08617.x

https://www.ncbi.nlm.nih.gov/pubmed/21496003 (opens new window)

The emerging role of fetal hemoglobin induction in non-transfusion-dependent thalassemia. (opens new window)

Thein SL.

Źródło‎: Blood Rev 2012;26 Suppl 1:S35-9.

Indeks‎: PubMed 22631042

DOI‎: 10.1016/S0268-960X(12)70011-5

https://www.ncbi.nlm.nih.gov/pubmed/22631042 (opens new window)